Methods of using macrocyclic modulators of the ghrelin receptor
View Patent ↗The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
1. A method of stimulating gastrointestinal motility comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of the following:
or pharmaceutically acceptable salts thereof.
2. The method of claim 1 , wherein the compound is administered orally.
3. The method of claim 1 , wherein the compound is administered parenterally.
4. The method of claim 3 , wherein the compound is administered intracranially.
5. The method of claim 1 , wherein the compound is co-administered with an additional agent useful for stimulating gastrointestinal motility.
6. A method of treating a gastrointestinal disorder comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of the following:
or pharmaceutically acceptable salts thereof.
7. The method of claim 6 , wherein the gastrointestinal disorder is characterized by gastrointestinal dysmotility.
8. The method of claim 6 , wherein the gastrointestinal disorder is postoperative ileus, gastroparesis, opioid-induced bowel dysfunction, chronic intestinal pseudo-obstruction, short bowel syndrome, emesis, constipation-predominant irritable bowel syndrome (IBS), delayed gastric emptying, gastroesophageal reflux disease (GERD), gastric ulcers, or Crohn's disease.
9. The method of claim 8 , wherein the gastroparesis is diabetic gastroparesis.
10. The method of claim 6 , wherein the compound is administered orally.
11. The method of claim 6 , wherein the compound is co-administered with an additional agent useful for treating a gastrointestinal disorder.
12. A method of treating postoperative ileus in a subject comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of the following:
or pharmaccuticaily acceptable salts thereof; whereinto compound is administered parenteraily.
13. The method of claim 12 , wherein the compound is administered intravenously.
14. The method of claim 12 , wherein the compound is administered subcutaneously.
15. A method of treating gastroparesis in a subject comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of the following:
or pharmaceutically acceptable salts thereof, wherein the compound is administered parenterally.
16. The method of claim 15 , wherein the gastroparesis is diabetic gastroparesis.
17. The method of claim 15 , wherein the compound is administered intravenously.
18. The method of claim 15 , wherein the compound is administered subcutaneously.